Sanofi takes its own drug pricing pledge, pointing to a decline in their aggregate net price
Sanofi CEO Sanofi Olivier Brandicourt (left), flanked by CFO Jerome Contamine, speaks during the presentation of the group’s 2016 results in Paris on February 8, 2017. ERIC PIERMONT/AFP/Getty
What do you do when your industry is routinely pilloried by the president of the US for being run by a group of white collar price gougers, routinely ripping off the American consumer?
In Big Pharma’s case, you begin to understand that those opaque drug prices you work with are a big part of the problem, and you start to shed a light on the pricing menu, while committing to an ethical approach on pricing that might help cool the white-hot rhetoric.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.